GLP-1 and obesity drug stocks

13 stocks · Healthcare sector

As of Nov 16, 2026: 13 stocks.

Sellers or developers of GLP-1 and other obesity drugs, like Ozempic, Wegovy, and Zepbound.

As of 7:52 PM ET after-hours, delayed 15+ min · Live for Pro members

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 13 GLP-1 and obesity drug stocks rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Eli Lilly & Co. in the news today

  • Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion, Bloomberg reports.

    LLY is 74% of GLP-1 and obesity drug stocks by value. 7:05 AM ET. GLP-1 and obesity drug stocks are down 5.3% on average today.

GLP-1 and obesity drug stocks, ranked by Quality Score

The theme's stocks
StockPriceQuality Score
Eli Lilly (LLY) logoLLYEli Lilly$1,431.67-0.82%19
Sells Zepbound and Mounjaro, GLP-1 drugs for obesity and diabetes.
Amgen (AMGN) logoAMGNAmgen$462.32-0.72%17
Develops MariTide, a GLP-1 based obesity shot in Phase 3 trials.
Rhythm Pharmaceuticals (RYTM) logoRYTMRhythm Pharmaceuticals$107.48-6.56%8
Sells Imcivree for severe obesity caused by rare genetic diseases.
Drugs on sale 1
Novo Nordisk (NVO) logoNVONovo Nordisk$41.60-0.07%
Sells Wegovy and Ozempic, GLP-1 drugs for obesity and diabetes.
Drugs in trials 7
Altimmune (ALT) logoALTAltimmune$1.56-5.17%
Develops pemvidutide, a GLP-1 and glucagon drug, for MASH liver disease.
Corbus Pharmaceuticals Holdings (CRBP) logoCRBPCorbus Pharmaceuticals$3.38-0.44%
Develops CRB-913, an obesity pill that blocks the CB1 receptor.
Structure Therapeutics (GPCR) logoGPCRStructure Therapeutics$18.57-7.15%
Develops aleniglipron, a GLP-1 pill for obesity in clinical trials.
Kailera Therapeutics (KLRA) logoKLRAKailera Therapeutics$12.57-5.28%
Develops ribupatide, a GLP-1 based obesity shot in Phase 3 trials.
MBX Biosciences (MBX) logoMBXMBX Biosciences$53.12-5.04%
Develops MBX 4291, a GLP-1 and GIP obesity shot meant for monthly dosing.
Viking Therapeutics (VKTX) logoVKTXViking Therapeutics$26.80-8.28%
Develops VK2735, a GLP-1 and GIP obesity shot in Phase 3 trials.
Wave Life Sciences (WVE) logoWVEWave Life Sciences$2.87-8.31%
Develops WVE-007, an RNA medicine for obesity in its first human trial.
Telehealth sellers 2
Hims & Hers Health (HIMS) logoHIMSHims & Hers Health$18.56-5.93%
Sells weight loss treatments, including GLP-1 drugs, through its app.
LifeMD (LFMD) logoLFMDLifeMD$1.85-15.72%
Runs a telehealth weight loss program built around GLP-1 drugs.
The other 10 Quality Scores, for Pro members. See them free →

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Why GLP-1 and obesity drug stocks are down this week

GLP-1 and obesity drug stocks fell a median 7.6% since the close on Nov 9 (13 stocks); the S&P 500 fell 1.7%.

What moved them

  • No single story: 11 of 13 fell with the market this week.
3 stocks' stories, for Pro members. See them free →

What moved today

GLP-1 and obesity drug stocks are down 5.3% on average, 13 of 13 down.

The news behind each move, for Pro members. See them free →

The week, against the S&P 500

What moves GLP-1 and obesity drug stocks

Trial results, FDA decisions, and prices drive the news.

  • Trial results and FDA decisions
  • Prices, and whether Medicare and insurers pay
  • Prescription numbers each quarter

Here is what Pro members see.

  • The same page for Pro members, on AI chips

    Each stock's price, move, next report, and Quality Score, live, with what it does in the theme.

  • The theme in the scanner

    Pick GLP-1 and obesity drugs under Theme in the scanner's filters, then narrow it by score, size, or any other filter.

  • An optional theme alert

    An optional alert when a GLP-1 and obesity drug stock reaches Excellent, by push, email, or the bell.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • The chart

    Candles or lines, the averages you pick, extra panes, and a day to the full history.

  • The score, added up

    Price action, the company, and signals, each with its points, summed into one number on every stock's page.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Questions about GLP-1 and obesity drug stocks

Why are GLP-1 and obesity drug stocks down this week?

GLP-⁠1 and obesity drug stocks fell a median 7.6% since the close on Nov 9 (13 stocks); the S&P 500 fell 1.7%. No single story: 11 of 13 fell with the market this week.

Which GLP-1 and obesity drug stocks fell most this week?

Altimmune (ALT) fell 26%, Hims & Hers Health (HIMS) fell 19%, and Wave Life Sciences (WVE) fell 18%.

How many GLP-1 and obesity drug stocks are there?

This list has 13. A stock is on it when it sells or is developing a GLP-⁠1 drug or another obesity medicine, or sells GLP-⁠1 prescriptions as a main line, and its annual report says so. Left out: device makers whose parts go into the pens, supplement sellers, and companies whose obesity program is a minor one.

Which GLP-1 and obesity drug stocks does Breakaway rank highest?

Eli Lilly (LLY) 19, Amgen (AMGN) 17, and Rhythm Pharmaceuticals (RYTM) 8, the highest Quality Scores of the 13. Breakaway ranks every stock by its Quality Score, which reads each company's numbers and its chart; the ranking is information, not advice, and each stock's page shows the reasons behind its score.

Which GLP-1 and obesity drug stocks are under $5?

4 of the 13 traded under $5 at the prices on this page: Altimmune (ALT) at $1.56, LifeMD (LFMD) at $1.85, Wave Life Sciences (WVE) at $2.87, and Corbus Pharmaceuticals Holdings (CRBP) at $3.38.

Which GLP-1 and obesity drug stocks pay a dividend?

3 of the 13 paid a regular cash dividend in the last 12 months: Eli Lilly (LLY), Amgen (AMGN), and Novo Nordisk (NVO).

Is there an ETF for GLP-1 and obesity drug stocks?

Yes, for one: the Amplify Weight Loss Drug & Treatment ETF (THNR) holds weight loss drug makers and their suppliers. This list is the companies themselves, each one ranked by its Quality Score.

Do these GLP-1 and obesity drug stocks trade in the US?

Yes. All 13 trade on US stock exchanges, in US dollars. One is a company from outside the US: Novo Nordisk (NVO).

Drug developers' FDA dates are on the FDA calendar. More in healthcare stocks, or every theme.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from Breakaway's Quality Scores and the market's prices. Updated Nov 16, 2026.

Free to reuse with a link to this page.

How to cite

Breakaway, GLP-1 and Obesity Drug Stocks List: 13 Companies, Ranked, Nov 16, 2026, getbreakaway.com/themes/glp-1

Journalists: email support@getbreakaway.com for the data behind this page.

The whole list, ranked live.

Every stock on this page with its Quality Score and its 14 chart checks, sorted your way, scored again every 15 seconds while the market is open.

See all 13 GLP-1 and obesity drug stocks ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

The list is checked against each company's annual report, last on Oct 2, 2026.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.